Canon Inc. Revenue & Financials

Revenue of $29.9 billion in 2024 compared to $29.1 billion in 2023 reflects modest organic growth in an environment where office printing volumes continue to decline and medical imaging investment is growing. Net income of $2.06 billion represents a 6.9% net margin — consistent with Canon's historical performance but below the 8-10% levels the company achieved in peak camera and imaging years. The medical systems segment, built primarily through the Toshiba Medical acquisition and subsequent organic investment, provides the most important structural upside: global hospital capital expenditure cycles are long, but the installed base of CT and MRI equipment requires maintenance contracts and consumables that generate recurring revenue for decades after the initial sale. Canon's portfolio of over 100,000 active patents across all segments provides a comparable advantage in enterprise printing and industrial optics. Canon's managed document service agreements feature non-cancellable terms of three to five years with built-in annual price escalation, creating a structural hedge against inflation across the printing business. These contracts embed Canon's hardware, software, and consumables into enterprise IT infrastructure in ways that make competitive displacement expensive and operationally disruptive. The market capitalization of $37 billion at roughly 1.2x revenue reflects the market's assessment of Canon as a mature industrial conglomerate in slow-growth markets. That assessment underweights the medical imaging growth trajectory and the NIL lithography option value. Whether NIL achieves commercial scale in semiconductor manufacturing is genuinely uncertain, but the downside of being wrong is limited — Canon's existing portfolio generates sufficient cash flow to fund the investment without financial strain.